425: Atlantic Coastal Acquisition Corp. II Secures $11.2 Million in PIPE Financing for Abpro Corporation Business Combination

Atlantic Coastal Acquisition Corp. II (ACAB) has entered into subscription agreements with Abpro Bio International Inc. and Celltrion, Inc. for a total of $11.2 million in PIPE financing to support its business combination with Abpro Corporation.

Summary

• Atlantic Coastal Acquisition Corp. II (ACAB) has entered into subscription agreements with Abpro Bio International Inc. and Celltrion, Inc. for a total of $11.2 million in PIPE (Private Investment in Public Equity) financing.
• Abpro Bio will purchase 622,467 newly-issued shares of ACAB Series A common stock at $10.00 per share, totaling $6,224,670.
• As part of the Abpro Bio agreement, $4,224,663.33 of a previously issued Company Loan will be forgiven.
• Celltrion will purchase 500,000 newly-issued shares of ACAB Series A common stock at $10.00 per share, totaling $5,000,000.
• Both Abpro Bio and Celltrion will receive additional shares of Series A common stock previously allocated for PIPE financing, with Abpro Bio receiving 1,244,934 shares and Celltrion receiving 1,000,000 shares.
• The PIPE financing is contingent upon the closing of the previously announced business combination between ACAB, Abpro Corporation, and Abpro Merger Sub Corp.
• The lock-up periods in the business combination agreement will not apply to the PIPE shares.
• ACAB will file a registration statement with the SEC to register the resale of the PIPE shares within 30 days after the closing.
• Celltrion and ACAB have entered into an Investor Rights Agreement, granting Celltrion the right to nominate a director to the surviving company's board at the next annual meeting.
• The securities issued in connection with the PIPE Subscription Agreements will not be registered under the Securities Act of 1933, relying on exemptions under Section 4(a)(2) and/or Regulation D.

Sentiment

Score: 7

Explanation: The announcement of PIPE financing is generally positive as it provides additional capital for the business combination. The involvement of strategic partners is also a positive signal. However, the relatively small size of the PIPE and the dependence on the closing of the business combination introduce some uncertainty.

Positives

• The PIPE financing provides additional capital to support the business combination with Abpro Corporation.
• The participation of Abpro Bio and Celltrion, existing partners of Abpro Corporation, demonstrates confidence in the business combination.
• Celltrion's right to nominate a director could bring valuable industry expertise to the board.
• The lock-up exemption for PIPE shares provides liquidity for the investors.
• The forgiveness of the Company Loan simplifies the capital structure.

Negatives

• The PIPE shares are being offered in a private placement, which may limit their immediate liquidity.
• The PIPE financing is contingent on the closing of the business combination, which is subject to various risks and uncertainties.
• The reliance on exemptions from registration under the Securities Act may limit the resale of the PIPE shares.

Risks

• The business combination with Abpro Corporation may not close, which would terminate the PIPE financing.
• Regulatory approvals for the business combination may be delayed or subject to unanticipated conditions.
• ACAB's stockholders may not approve the business combination.
• The combined company may not realize the anticipated benefits of the business combination.
• Redemption requests by ACAB's stockholders could reduce the amount of available capital.
• General economic, financial, legal, political, and business conditions could adversely affect the combined company.
• The combined company may face competition and other risks related to its business.

Future Outlook

The document outlines the PIPE financing agreements and the Investor Rights Agreement, which are contingent upon the successful completion of the business combination. The company anticipates filing a registration statement for the resale of the PIPE shares within 30 days of the closing.

Industry Context

The announcement reflects a common strategy for SPACs (Special Purpose Acquisition Companies) to secure additional funding through PIPE investments to ensure sufficient capital for the target company upon completion of the business combination. The involvement of existing strategic partners like Celltrion is a positive signal for the deal's prospects.

Comparison to Industry Standards

• PIPE financings are a common mechanism for SPACs to raise capital, particularly in the biotech sector.
• Comparable companies that have utilized PIPE financings in connection with SPAC mergers include companies such as 23andMe (with a $250 million PIPE) and Sema4 (with a $300 million PIPE).
• The size of the PIPE financing ($11.2 million) is relatively small compared to some other SPAC deals, which may indicate a smaller capital need or a more challenging fundraising environment.
• The involvement of strategic investors like Celltrion is a positive sign, as it suggests a strong alignment of interests and potential for future collaboration.

Corporate Governance

Related Party Transactions

• Abpro Bio holds an approximately 35% ownership interest in Abpro Corporation.
• Abpro Bio previously entered into a Collaboration and License Agreement with Abpro Corporation in January 2020 and made a $30 million equity investment.
• Abpro Corporation issued a promissory note in the aggregate principal amount of up to $6 million for the benefit of Abpro Bio International.
• Celltrion has previously entered into an exclusive collaboration and license agreement with Abpro Corporation in September 2022, which was amended in August 2024, and is entitled to certain milestone payments from the Company thereunder.

Stakeholder Impact

• Shareholders of ACAB will be impacted by the dilution from the issuance of new shares in the PIPE financing.
• Shareholders of Abpro Corporation will be impacted by the business combination and the resulting ownership structure.
• Employees of Abpro Corporation and ACAB may be impacted by the integration of the two companies.
• Customers and suppliers of Abpro Corporation may be impacted by the changes resulting from the business combination.

Next Steps

• ACAB will file a registration statement with the SEC to register the resale of the PIPE shares within 30 days after the closing.
• ACAB will seek stockholder approval for the business combination.
• The business combination between ACAB, Abpro Corporation, and Abpro Merger Sub Corp. is expected to close.

Key Dates